Post operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.

For patients who have undergone surgery for high-risk skin cancer of the head and neck, this study aims to determine whether there is a difference in time to loco-regional relapse (cancer coming back in the same area) between patients treated with concurrent chemo-radiotherapy (using the chemo drug Carboplatin) versus those participants who were treated with radiotherapy alone.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

321

Trial Chairperson

Professor Sandro Porceddu,
Princess Alexandra Hospital,
QLD

Clinical Trial Registration

Related Post

27 October, 2026

MASTERPLAN trial shows benefit from SBRT in pancreatic cancer

LATEST NEWS: 27 October 2026 Findings from the AGITG/TROG

21 October, 2026

Jess’s deeply personal reason for joining TROG’s Km’s for Cancer Research challenge

LATEST NEWS: 21 October 2026 For Jess Synge, taking